771583-12-1

Basic information

• Product Name: 2-(AMINOMETHYL)-4-BROMOANILINE
• Synonyms: RARECHEM AL BW 1235;2-(AMINOMETHYL)-4-BROMOANILINE;2-(Aminomethyl)-4-boroaniline;2-AMinoMethyl-4-broMophenylaMine;Benzenemethanamine,2-amino-5-bromo-
• CAS NO: 771583-12-1
• Molecular Formula: C₇H₉BrN₂
• Molecular Weight: 201.06
• Mol File: 771583-12-1.mol

Chemical Properties

• Boiling Point: 308.5±27.0 °C(Predicted)
• Appearance: /
• Density: 1.572±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.30±0.10(Predicted)
• CAS DataBase Reference: 2-(AMINOMETHYL)-4-BROMOANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(AMINOMETHYL)-4-BROMOANILINE(771583-12-1)
• EPA Substance Registry System: 2-(AMINOMETHYL)-4-BROMOANILINE(771583-12-1)

Safety Data

• Hazardous Substances Data: 771583-12-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-(AMINOMETHYL)-4-BROMOANILINE is used as a building block in organic synthesis for the creation of various organic compounds. Its presence of both an amine and bromine functional groups makes it versatile for synthesizing a wide range of products.
Used in Pharmaceutical Research:
In pharmaceutical research, 2-(AMINOMETHYL)-4-BROMOANILINE is utilized as a key intermediate in the development of new pharmaceuticals. Its unique structure allows for the exploration of its potential therapeutic properties and applications in medicine.
Used in Dye and Pigment Manufacturing:
2-(AMINOMETHYL)-4-BROMOANILINE is used as a starting material in the manufacturing of dyes and pigments. Its chemical properties contribute to the color and stability of these products, making it valuable in the dye and pigment industry.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, 2-(AMINOMETHYL)-4-BROMOANILINE is used as a precursor in the production of various drugs. Its role in the synthesis of active pharmaceutical ingredients highlights its importance in the development of new medications.

Upstream product

• 39263-32-6 2-amino-5-bromobenzonitrile 
• 1004997-73-2 2-(aminomethyl)-4-bromoaniline dihydrochloride 

Downstream Products

• 1004997-73-2 2-(aminomethyl)-4-bromoaniline dihydrochloride 
• 1428149-50-1 6'-bromo-4-((4-methoxybenzyl)oxy)-3',4'-dihydro-1'H-spiro[cyclohexane-1,2'-quinazoline] 
• 1428149-59-0 2-bromo-8-((4-methoxybenzyl)oxy)-6,7,8,9,10,12-hexahydroazepino[2,1-b]quinazoline 
• 1201902-24-0 6-bromo-2-phenyl-3,4-dihydroquinazoline 
• 1201902-00-2 [6-(2-methyl-1H-imidazol-1-yl)-2-phenyl]quinazoline 
• 1004997-71-0 [2-phenyl-6-(1H-imidazol-1-yl)]quinazoline 
• 1228552-83-7 [(S)-1-((S)-2-{5-[4-(6-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methylbutyryl)-pyrrolidin-2-yl]-3H-imidazol-4-yl}-quinazolin-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]carbamic acid methyl ester 
• 1261071-79-7 tert-butyl (2S)-2-(5-{2-[4-(2-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-5-yl)phenyl]quinazolin-6-yl}-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1228552-80-4 (S)-2-[5-(4-{6-[2-((S)-1-carboxylic acid tert-butyl ester-pyrrolidin-2-yl)-3H-imidazol-4-yl]quinazolin-2-yl}phenyl)-1H-imidazol-2-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1261071-78-6 (S)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-[2-(4-{6-[2-((S)-1-carboxylic acid tert-butyl-ester-pyrrolidine-2-carbonyloxy)acetyl]quinazolin-2-yl}phenyl)-2-oxoethyl] ester 
• 1261071-77-5 2-bromo-1-{2-[4-(2-bromoacetyl)phenyl]quinazolin-6-yl}ethanone 
• 1261071-76-4 2,2-dibromo-1-{2-[4-(2,2-dibromoacetyl)phenyl]quinazolin-6-yl}ethanone 
• 1261071-75-3 6-(1-ethoxyethenyl)-2-[4-(1-ethoxyethenyl)phenyl]quinazoline 
• 1261071-74-2 1-[2-(4-acetylphenyl)-quinazolin-6-yl]-ethanone 

Relevant articles and documents

Base-Promoted Synthesis of 2-Aryl Quinazolines from 2-Aminobenzylamines in Water

A transition-metal-free procedure for the synthesis of a highly valuable class of heteroaromatics, quinazolines, was developed by using easily available 2-aminobenzylamines and α,α,α-trihalotoluenes. The transformation proceeded smoothly in the presence of only sodium hydroxide and molecular oxygen in water at 100 °C, furnishing a variety of 2-aryl quinazolines. The crystallization process of the crude reaction mixture for the purification of the solid products circumvents huge solvent-consuming workup and column chromatographic techniques, which make the overall process more sustainable and economical.

Chrysene derivative containing quinazoline group and application thereof

The invention relates to a chrysene derivative containing a quinazoline group. The structure of the chrysene derivative is shown in the formula (1). The chrysene derivative containing the quinazoline group is suitable for serving as an ETL material in an

Derisking the Cu-Mediated 18F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands

Molecules labeled with fluorine-18 (18F) are used in positron emission tomography to visualize, characterize and measure biological processes in the body. Despite recent advances in the incorporation of 18F onto arenes, the development of general and efficient approaches to label radioligands necessary for drug discovery programs remains a significant task. This full account describes a derisking approach toward the radiosynthesis of heterocyclic positron emission tomography (PET) radioligands using the copper-mediated 18F-fluorination of aryl boron reagents with 18F-fluoride as a model reaction. This approach is based on a study examining how the presence of heterocycles commonly used in drug development affects the efficiency of 18F-fluorination for a representative aryl boron reagent, and on the labeling of more than 50 (hetero)aryl boronic esters. This set of data allows for the application of this derisking strategy to the successful radiosynthesis of seven structurally complex pharmaceutically relevant heterocycle-containing molecules.

6-PIPERAZINYL-3,4-DIHYDROQUINAZOLIN-2(1H)-ONES

A series of new 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones have been synthesized. The compounds are structurally related to adoprazine, a potential atypical antipsychotics bearing potent D2 receptor antagonist and 5-HT1A receptor

Ynthesis of 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones

A series of new 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones have been synthesized. The described compounds are structurally related to adoprazine, a potential atypical antipsychotics bearing potent D2 receptor antagonist and 5-HT1A receptor agonist pro

HEPATITIS C VIRUS INHIBITORS

The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HCV replication.

Structure-activity relationships of highly cytotoxic copper(II) complexes with modified indolo[3,2- c ]quinoline ligands

A number of indolo[3,2-c]quinolines were synthesized and modified at the lactam unit to provide a peripheral binding site able to accommodate metal ions. Potentially tridentate ligands HL1a-HL4a and HL 1b-HL4b w

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS

The present invention is directed to 6-(1H-imidazo-1-yl)-2-aryl and 2-heteroaryl quinazoline and quinolines derivatives, compounds of formula (I), their pharmaceutical acceptable salts and solvates and corresponding pharmaceutical compositions, that acts

6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS

The present invention is directed to novel 6-lH-imidazo-2- aryl and 2-heteroaryl quinazoline and quinoline of Formula (I), corresponding salts and solvates thereof, to a process for their preparation and to the use of this compounds and corresponding phar